This was a multi-center, open-label, parallel-group trial. Eligible patients were enrolled at the central registration center and were randomized to receive either of two doses of valsartan (80 or 160 ...
Please provide your email address to receive an email when new articles are posted on . At week 52, resmetirom outperformed placebo in resolution of metabolic dysfunction-associated steatohepatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback